BECTON DICKINSON & CO reported revenue of $4.98B for the period ended 2026-06-30, -9.5% year on year. Net income was $0.38B, a 7.6% net margin on a 46.5% gross margin. The largest revenue line is Medical Essentials at 34% of the total. Free cash flow for the period was $0.51B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | $4.98B | -9.5% |
| Gross profit | $2.31B | — |
| Operating income | $0.66B | — |
| Net income | $0.38B | -34.3% |
| Gross margin | 46.5% | Net margin 7.6% |
| Revenue Q/Q | +5.7% | — |
| Segment | Revenue | Share |
|---|---|---|
| Medical Essentials | $1.68B | 33.6% |
| Interventional | $1.41B | 28.4% |
| Connected Care | $1.22B | 24.6% |
| Bio Pharma Systems | $0.67B | 13.4% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | $2.67B | 53.5% |
| R&D | $0.26B | 5.2% |
| SG&A | $1.26B | 25.3% |
| Tax & other | $0.29B | 5.7% |
| Item | Amount |
|---|---|
| Total assets | $50.73B |
| Total liabilities | $26.32B |
| Shareholders' equity | $24.42B |
| Equity / assets | 48.1% |
| Operating cash flow | $0.65B |
| Capital expenditure | $0.14B |
| Free cash flow | $0.51B |
| Cash conversion (OCF / net income) | 173% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
BRK.B ・ BBY ・ TECH ・ BIIB ・ BLK ・ BX ・ XYZ ・ BNY ・ BA ・ BKNG ・ BSX ・ BMY
Source: SEC EDGAR · This page shows public filing data only, not investment advice. · Browse all companies